ID

27815

Beschrijving

Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00558493

Link

https://clinicaltrials.gov/show/NCT00558493

Trefwoorden

Versies (1)
  1. 30-11-17 30-11-17 -
Houder van rechten

See clinicaltrials.gov

Geüploaded op

30 november 2017

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Chronic Hepatitis B NCT00558493

Engels

Eligibility Chronic Hepatitis B NCT00558493

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
hbv dna > 2,000 copies/ml at screening
Beschrijving

Hepatitis B DNA Measurement

Datatype

boolean

Alias
UMLS CUI [1]
C3641250
patients who have compensated liver disease (child-pugh score =<6)
Beschrijving

Compensated liver disease Child-Pugh - Total Score

Datatype

boolean

Alias
UMLS CUI [1,1]
C3839044
UMLS CUI [1,2]
C4055253
patients without lmv resistant mutation by rfmp assay
Beschrijving

Absence Mutation Lamivudine Resistant | Other Coding

Datatype

boolean

Alias
UMLS CUI [1,1]
C0332197
UMLS CUI [1,2]
C0026882
UMLS CUI [1,3]
C0209738
UMLS CUI [1,4]
C0332325
UMLS CUI [2]
C3846158
patients who have not experienced viral breakthrough at consecutive two measurements (at least one month apart) during lamivudine monotherapy
Beschrijving

Viral Breakthrough Absent Measurement Quantity | Lamivudine

Datatype

boolean

Alias
UMLS CUI [1,1]
C4053869
UMLS CUI [1,2]
C0332197
UMLS CUI [1,3]
C0242485
UMLS CUI [1,4]
C1265611
UMLS CUI [2]
C0209738
patients who can submit the written consent and comply with the claims postulated of this clinical trial
Beschrijving

Informed Consent | Protocol Compliance

Datatype

boolean

Alias
UMLS CUI [1]
C0021430
UMLS CUI [2]
C0525058
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
currently receiving antiviral except lmv or corticosteroid therapy
Beschrijving

Antiviral Therapy | Exception Lamivudine | Exception Steroid therapy

Datatype

boolean

Alias
UMLS CUI [1]
C0280274
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0209738
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0149783
patients that previously received antiviral treatment for hepatitis b other than lamivudine in the proceeding 12 months
Beschrijving

Antiviral Therapy Hepatitis B | Exception Lamivudine

Datatype

boolean

Alias
UMLS CUI [1,1]
C0280274
UMLS CUI [1,2]
C0019163
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0209738
previous treatment with interferon or other immunomodulatory therapies must have ended at least 6 months preceding the study screening
Beschrijving

Interferon To be stopped | Immunomodulation To be stopped

Datatype

boolean

Alias
UMLS CUI [1,1]
C3652465
UMLS CUI [1,2]
C1272691
UMLS CUI [2,1]
C1963758
UMLS CUI [2,2]
C1272691
treatment with nephrotoxic drugs, competitors of renal excretion, and/or hepatotoxic drugs within 2 months before study screening or during the study period
Beschrijving

Pharmaceutical Preparations Nephrotoxic | Pharmaceutical Preparations Hepatotoxicity

Datatype

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C1514118
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0235378
patients who is co-infected with hcv, hdv or hiv
Beschrijving

HCV coinfection | HDV Coinfection | HIV coinfection

Datatype

boolean

Alias
UMLS CUI [1]
C1698259
UMLS CUI [2,1]
C0011220
UMLS CUI [2,2]
C0275524
UMLS CUI [3]
C4062778
serious concurrent medical conditions
Beschrijving

Other medical condition Serious

Datatype

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C0205404
prior organ transplantation
Beschrijving

Organ Transplantation

Datatype

boolean

Alias
UMLS CUI [1]
C0029216
patient has creatinine clearance less than 60ml/min as estimated by the following formula:
Beschrijving

Estimation of creatinine clearance by Cockcroft-Gault formula

Datatype

boolean

Alias
UMLS CUI [1]
C2711451
[(140-age in years) (body weight [kg])] / [(72) (serum creatinine] [mg/dl])[note: multiply estimates by 0.85 for women]
Beschrijving

Estimation of creatinine clearance by Cockcroft-Gault formula | Gender

Datatype

boolean

Alias
UMLS CUI [1]
C2711451
UMLS CUI [2]
C0079399
Terug naar het begin van de pagina

Similar models

Eligibility Chronic Hepatitis B NCT00558493

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Hepatitis B DNA Measurement
Item
hbv dna > 2,000 copies/ml at screening
boolean
C3641250 (UMLS CUI [1])
Compensated liver disease Child-Pugh - Total Score
Item
patients who have compensated liver disease (child-pugh score =<6)
boolean
C3839044 (UMLS CUI [1,1])
C4055253 (UMLS CUI [1,2])
Absence Mutation Lamivudine Resistant | Other Coding
Item
patients without lmv resistant mutation by rfmp assay
boolean
C0332197 (UMLS CUI [1,1])
C0026882 (UMLS CUI [1,2])
C0209738 (UMLS CUI [1,3])
C0332325 (UMLS CUI [1,4])
C3846158 (UMLS CUI [2])
Viral Breakthrough Absent Measurement Quantity | Lamivudine
Item
patients who have not experienced viral breakthrough at consecutive two measurements (at least one month apart) during lamivudine monotherapy
boolean
C4053869 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0242485 (UMLS CUI [1,3])
C1265611 (UMLS CUI [1,4])
C0209738 (UMLS CUI [2])
Informed Consent | Protocol Compliance
Item
patients who can submit the written consent and comply with the claims postulated of this clinical trial
boolean
C0021430 (UMLS CUI [1])
C0525058 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Antiviral Therapy | Exception Lamivudine | Exception Steroid therapy
Item
currently receiving antiviral except lmv or corticosteroid therapy
boolean
C0280274 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0209738 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0149783 (UMLS CUI [3,2])
Antiviral Therapy Hepatitis B | Exception Lamivudine
Item
patients that previously received antiviral treatment for hepatitis b other than lamivudine in the proceeding 12 months
boolean
C0280274 (UMLS CUI [1,1])
C0019163 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0209738 (UMLS CUI [2,2])
Interferon To be stopped | Immunomodulation To be stopped
Item
previous treatment with interferon or other immunomodulatory therapies must have ended at least 6 months preceding the study screening
boolean
C3652465 (UMLS CUI [1,1])
C1272691 (UMLS CUI [1,2])
C1963758 (UMLS CUI [2,1])
C1272691 (UMLS CUI [2,2])
Pharmaceutical Preparations Nephrotoxic | Pharmaceutical Preparations Hepatotoxicity
Item
treatment with nephrotoxic drugs, competitors of renal excretion, and/or hepatotoxic drugs within 2 months before study screening or during the study period
boolean
C0013227 (UMLS CUI [1,1])
C1514118 (UMLS CUI [1,2])
C0013227 (UMLS CUI [2,1])
C0235378 (UMLS CUI [2,2])
HCV coinfection | HDV Coinfection | HIV coinfection
Item
patients who is co-infected with hcv, hdv or hiv
boolean
C1698259 (UMLS CUI [1])
C0011220 (UMLS CUI [2,1])
C0275524 (UMLS CUI [2,2])
C4062778 (UMLS CUI [3])
Other medical condition Serious
Item
serious concurrent medical conditions
boolean
C3843040 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
Organ Transplantation
Item
prior organ transplantation
boolean
C0029216 (UMLS CUI [1])
Estimation of creatinine clearance by Cockcroft-Gault formula
Item
patient has creatinine clearance less than 60ml/min as estimated by the following formula:
boolean
C2711451 (UMLS CUI [1])
Estimation of creatinine clearance by Cockcroft-Gault formula | Gender
Item
[(140-age in years) (body weight [kg])] / [(72) (serum creatinine] [mg/dl])[note: multiply estimates by 0.85 for women]
boolean
C2711451 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial